The new technologies of radionuclide therapy are allowing for personalized treatment of various forms of cancer. Learn more about the clinical utility of these procedures and earn free CE credit.
Welcome to our Healthcare Provider portal. Everything you need to understand the advantages and applications of nuclear medicine and molecular imaging in your practice. Find out more about ordering the right test for the right patient at the right time.
Molecular imaging is a type of medical imaging that provides detailed pictures of what is happening inside the body at the molecular and cellular level. Where other diagnostic imaging procedures—such as x-rays, computed tomography (CT) and ultrasound—offer pictures of physical structure, molecular imaging allows physicians to see how the body is functioning and to measure its chemical and biological processes.
Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials (radiopharmaceuticals) to diagnose and treat disease. In nuclear medicine imaging, the radiopharmaceuticals are detected by special types of cameras that work with computers to provide very precise pictures of the area of the body being imaged. Nuclear medicine can also be used to treat certain types of cancer and other diseases.
Molecular imaging offers unique insights into the human body that enable physicians to personalize patient care. In terms of diagnosis, molecular imaging is able to:
SNMMI has created guidelines to identify those elements of the procedure that are most important in obtaining a high-quality examination, Appropriate Use Criteria (AUC), and is working towards optimizing dose.
The SNMMI PET Center of Excellence has created a go-to resource with in-depth ordering information and printable materials related to PET and PET/CT, including:
SNMMI is dedicated to providing the community with access to the most knowledgeable and experienced speakers in the field of nuclear medicine and molecular imaging. As part of the new Outreach Program, SNMMI is working to enhance relationships with relevant societies and patient organizations. We have created a pool of speakers who can speak at your next meeting. Please complete the form below to request a speaker.
SNMMI and the North American Neuroendocrine Tumor Society (NANETS) held their first joint symposium to provide an in-depth review of the clinical utility of the nuclear medicine technologies for NETs.
New research presented at the European College of Neuropsychopharmacology Congress in Berlin sheds light on what happens in the brains of gamblers.
(MI: Making a Difference)
The prostate cancer drug radium-223 (Xofigo) is temporarily unavailable due to a manufacturing issue. The FDA Drug Shortage website indicates that the drug shortage was first reported October 7.
While CT and MR are still the mainstays of detecting ischemic stroke, several SPECT and PET imaging techniques have been developed and are on the way to add comprehensive clinical information in the case of cerebrovascular disease. With this in mind, hybrid imaging such as PET/MR could provide a best-possible map of variables involved in stroke, according to a review published Oct. 9 in the Journal of Nuclear Medicine .
(MI: Making a Difference)
Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.
SNMMI monitors multiple federal legislative issues and provides resources including issue summaries, letters to Congress, and analysis.
Learn more about journals published by or sponsored by the Society of Nuclear Medicine and Molecular Imaging.